-
2024-514152-32-00
3
2025-10-06
Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL) and Smal
-
2025-521023-75-00
4
2025-10-03
Immune system diseases
-
2025-521975-30-00
4
2025-10-03
Newly Diagnosed Multiple Myeloma
-
2025-520499-24-00
5
2025-10-01
Moderate to Severe Platysma Prominence
-
2024-511983-97-00
4
2025-09-29
Adult patients with indolent MCL who have not previously received trea
-
2024-512177-27-01
5
2025-09-29
High-risk Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invas
-
2024-520210-21-00
5
2025-09-19
Crohn’s Disease
-
2025-520672-26-00
9
2025-09-16
Gastrointestinal Neoplasms
-
2024-516982-35-00
5
2025-09-11
Ovarian Cancer
-
2024-514186-18-00
1
2025-09-09
Systemic Lupus Erythematosus
-
2023-508875-35-00
5
2025-09-01
Heart condition
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2024-518276-32-00
4
2025-08-29
Locally advanced and unresectable Stage III non-small cell lung cancer
-
2024-519928-24-00
4
2025-08-21
Myelodysplastic Syndrome
-
2023-507071-21-01
1
2025-08-14
Relapsed/Refractory Multiple Myeloma
-
2024-512132-29-00
4
2025-08-06
Metastatic castration-resistant prostate cancer
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2023-509630-19-00
5
2025-07-31
Esophageal Squamous Cell Carcinoma (ESCC)
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2025-520743-33-00
9
2025-07-23
Advanced/metastatic colorectal cancer
-
2024-515098-93-00
5
2025-07-22
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML
-
2024-519322-20-00
5
2025-07-21
metastatic colorectal cancer
-
2024-516162-11-00
5
2025-07-14
Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
-
2024-512981-33-00
4
2025-07-09
Metastatic Colorectal Cancer